Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have lung cancer that is mostly not “squamous” type.
- After surgery, your cancer must be classified as Stage IB, II, or IIIA using pathology (surgical lab) results.
- Your tumor test must show an EGFR mutation such as Ex19del or L858R (and may include other EGFR changes).
- Your lung tumor must be completely removed with no visible disease left, with negative (clear) surgical margins.
- You must be well enough to do normal activities (Performance Status 0–1) and fully recovered from surgery and any standard post-op treatment.
- You must not have had any prior cancer treatment for this cancer (including chemotherapy or EGFR medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests giving Furmonertinib (an oral targeted therapy) before surgery to shrink tumors in people with a specific EGFR gene mutation in their non-small cell lung cancer. The goal is to make surgery more effective and improve outcomes.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests whether combining an EGFR-targeting drug (furmonertinib) with either ablation or radiation therapy can help patients with early-stage lung cancer who cannot have surgery or choose not to. The goal is to see if this combination approach works better than treatment alone.
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
Hear when a new Non-small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.